Classifications

• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K49/00—Preparations for testing in vivo
  • A61K49/001—Preparation for luminescence or biological staining
  • A61K49/0013—Luminescence
  • A61K49/0017—Fluorescence in vivo
  • A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
  • A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
  • A61K49/0026—Acridine dyes
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K49/00—Preparations for testing in vivo
  • A61K49/001—Preparation for luminescence or biological staining
  • A61K49/0013—Luminescence
  • A61K49/0017—Fluorescence in vivo
  • A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
  • A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
  • A61K49/0036—Porphyrins
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K49/00—Preparations for testing in vivo
  • A61K49/001—Preparation for luminescence or biological staining
  • A61K49/0013—Luminescence
  • A61K49/0017—Fluorescence in vivo
  • A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
  • A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
  • A61K49/0039—Coumarin dyes
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K49/00—Preparations for testing in vivo
  • A61K49/001—Preparation for luminescence or biological staining
  • A61K49/0013—Luminescence
  • A61K49/0017—Fluorescence in vivo
  • A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
  • A61K49/0056—Peptides, proteins, polyamino acids
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07K—PEPTIDES
  • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
  • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
  • C07K14/76—Albumins
  • C07K14/765—Serum albumin, e.g. HSA
• • G—PHYSICS
  • G01—MEASURING; TESTING
  • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
  • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
  • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
  • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
  • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
  • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
  • G01N33/54353—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals with ligand attached to the carrier via a chemical coupling agent
• • G—PHYSICS
  • G01—MEASURING; TESTING
  • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
  • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
  • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
  • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
  • G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
  • G01N33/582—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances with fluorescent label
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07K—PEPTIDES
  • C07K2319/00—Fusion polypeptide
• • G—PHYSICS
  • G01—MEASURING; TESTING
  • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
  • G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
  • G01N21/62—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light
  • G01N21/63—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light optically excited
  • G01N21/64—Fluorescence; Phosphorescence

Definitions

• the invention relates to conjugates for distinguishing diseased and healthy tissue, methods for producing such conjugates and their use
• pathological tissue e.g. B. from tumors
• the removal of the same is often an essential step. To do this, it is necessary for the operating doctor to recognize exactly where pathological tissue ends and healthy tissue begins. However, this is often not possible. Outflow of the pathological tissue is therefore overlooked, which then forms the basis for the re-emergence of the pathological tissue
• the present invention is therefore based on the object of providing a means with which pathological and healthy tissue can be distinguished
• the present invention thus relates to a conjugate comprising a compound capable of fluorescence and a carrier, the compound and the carrier being connected via an acid ester or acid amide bond or enane bridge (Schiff base) and the compound being an excitation wave ge of 630 nm or larger and / or 450 nm or smaller.
• a conjugate comprising a compound capable of fluorescence and a carrier, the compound and the carrier being connected via an acid ester or acid amide bond or enane bridge (Schiff base) and the compound being an excitation wave ge of 630 nm or larger and / or 450 nm or smaller.
• carrier includes compounds of any sort ⁇ dung herd or in superficial smaller vessels, such Neovasku- la ⁇ sationen in the region of the cornea (cornea of the eye) for the enrichment of the conjugate in a particular tissue, for example a tumor, a inflammations suitable are Games of such carriers are proteins and polyethers.
• the carrier may have hydroxyl or amino groups to form the acid ester or acid amide bond with the compound capable of fluorescence.
• the proteins are preferably not considered foreign to the body. They can be in native form. In the native form, the proteins have no inter- and / or intramolecular cross-linking.
• the proteins advantageously have a molecular weight of up to 1 000 000 daltons, in particular 30 000 to 1 000 000 daltons. It is also advantageous if the proteins are human proteins. Examples of the proteins are albumin, fibrinogen, transferrin, immunoglobulins and lipoproteins, with human serum albumin (HSA) being preferred. Fragments of the above proteins can also be used.
• the sequence of the proteins or fragments thereof can have changes in one or more amino acids compared to known sequences of the proteins or fragments thereof.
• polyethers examples are polyethylene glycols, especially those with a molecular weight of 100 to 20,000 daltons.
• the polyethylene glycols are preferably esterified or etherified at the terminal hydroxyl group with a C 1 -C 12 -alkyl group, in particular with a methyl group.
• a conjugate according to the invention can have one or more, in particular 2 to 4, the above carriers. If there are several carriers, they can be the same or different from one another. If there are several polyethers, these are advantageously chosen so that the molecular weight of all polyethers is approximately 20,000 daltons or more.
• the term "for fluorescence-capable compound” includes compounds of any kind that can be excited to fluoresce. These compounds can also be photoactive.
• the compound is attached to the support via an acid ester or acid amide bond or enane bridge.
• the compound capable of fluorescence can contain an acid group, e.g. Legs Have carbon, sulfone, phosphonic or Arson acid group, a hydroxyl group, an amino group or an aldehyde group. There may be several of these groups, which may be the same or different from one another.
• the compound capable of fluorescence is excited at a wavelength of 630 nm or greater, preferably 630 to 850 nm and particularly preferably 650 to 850 nm and / or at a wavelength of 450 nm or less, preferably 320 to 450 nm.
• These wavelengths relate to excitation wavelengths which the compound capable of fluorescence has in the conjugate according to the invention; in free form their excitation wavelength can deviate from this.
• porphyrins such as tetrasulfophenylporphyrin (TSPP; excitation wavelength 650 nm when bound to HSA), chlorines, bacteriochlorins, chlorophylls, phthalocyanines, these compounds being able to have metal ions as the central atom.
• TSPP tetrasulfophenylporphyrin
• acridinecarboxylic acid such as acridine-9-carboxylic acid
• coumaric acid such as coumarin 343, coumarin-3-carboxylic acid and hydroxycoumarin acetic acid (excitation wavelength 365 nm when bound to HSA), and indocyanine green (excitation wavelength 805 nm when bound to HSA), as well as derivatives of the above compounds.
• One or more of the compounds capable of fluorescence can be present in the conjugate according to the invention. If there are several, they can be the same or different from each other.
• FIGS. 1 to 3 Particularly preferred conjugates according to the invention are shown in FIGS. 1 to 3.
• Conjugates of the invention may be prepared by reacting the compound capable fluorescence for connection with the carrier to form a shiftureester ⁇ or acid amide bond is covalently linked. Suitable processes and materials required for this purpose are known to the person skilled in the art.
• the conjugates can be prepared by reacting this compound with carbodiimide and hydroxysuccinimide to form reactive succinimidyl esters and then reacting them with the carrier.
• the succinimidyl esters can be prepared jointly or separately.
• the reaction with the compound capable of fluorescence with carbodiimide and hydroxysuccinimide is carried out in a polar aprotic solvent, preferably dimethylformamide or dimethyl sulfoxide (DMSO).
• a polar aprotic solvent preferably dimethylformamide or dimethyl sulfoxide (DMSO).
• the molar ratio of to the fluorescent compound: carbodiimide: hydroxysuccinimide is about 1: 1, 5-3: 5- 1 0.
• the succinimidyl ester formed is then in an aqueous buffer solution, preferably NaHC0 3 , with the carrier, such as albumin, implemented.
• the carrier concentration is approximately 10 to 70 mg / ml.
• the acid group activated in this way can then react with the formation of acid amide or acid ester bonds with OH and NH groups of the carrier, conjugates according to the invention being obtained.
• the conjugates can be cleaned several times, e.g. B. by ultrafiltration, and finally sterile filtered
• Conjugates according to the invention are distinguished by an increased half-life in the organism. Furthermore, conjugates according to the invention accumulate in pathological tissue, in particular in tumor tissue, in inflammation centers and in superficial smaller vessels, e.g. B. from neovascularizations in the cornea. The compound that is capable of fluorescence is excited by light, whereby pathological tissue can be made visible, whereas healthy tissue in which the conjugates according to the invention do not accumulate is not made visible. Furthermore, there is no interference from the inherent fluorescence of the blood or of tissue, for example the liver, which does not distort the visual impression. Furthermore, conjugates according to the invention, in which the compound capable of fluorescence can be excited at 630 nm or greater, have a high depth of penetration. Brief description of the drawings:
• FIG. 1 shows the preparation of a conjugate from acridine-9-carboxylic acid and human serum albumin
• Figure 2 shows the preparation of a conjugate from coumarin 343 and human serum albumin
• Figure 3 shows the preparation of a conjugate from tetrasulfophenylporphin and human serum albumin.
• acridine-9-carboxylic acid hydrate (A9CS) were dissolved in 2 ml of DMSO and about 1 00 mg of N-hydroxysuccinimide (HSI) in a molar ratio of about 10/1 and 30 mg of N, N'-dicyclohexylcarbodiimide (DCC) in a molar ratio of about 1.5 / 1 added.
• HSU N-hydroxysuccinimide
• DCC N'-dicyclohexylcarbodiimide
• the ester becomes a solution of 2 g of human serum albumin (HSA), which is in 1 0 ml of original solution, 1 0 ml of 0.34 M NaHC0 3 and 1 0 ml of methoxypolyethylene glycol (MPEG) is slowly added.
• HSA human serum albumin
• MPEG methoxypolyethylene glycol
• the separation of the undesired accompanying substances in the finished preparation is carried out by ultrafiltration (exclusion limit 1 0 kD) with at least 4 washes.
• Example 2 Preparation of a conjugate according to the invention from coumarin 343 and human serum albumin
• Example 3 Preparation of a conjugate according to the invention from tetra- (4-sulfophenyD-porphin and human serum albumin
• Tetra- (4-sulfophenyl) porphine was dissolved in DMSO at a concentration of 10 mg / ml. Three times the molar amount of DCC and five times the molar amount of HSI was added to the clear dark green solution. After a reaction time of about 3 to 4 hours, the conversion to the TSPP succinimidyl ester (TSPP-SE) has ended, the di-cyclohexylurea formed being deposited in fine particles.
• the analytical control is carried out by means of thin layer chromatography.
• Human serum albumin (HSA, 4g, ie 2 ampoules of 2 g each in 10 ml) were diluted with 2 x 1 0 ml 0, 1 7 M NaHCO 3 and 20 ml methoxypolyethylene glycol 350 and placed in a 100 ml Erlenmeyer flask.
• the above TSPP-SE solution in DMSO was slowly added to this HSA solution with constant stirring, the initially clear solution becoming cloudy as a result of unreacted DCC which is insoluble in aqueous solution.
• the reaction mixture was stirred at room temperature for 30 minutes to complete the reaction.
• the turbidity was then checked using a sterile filter unit (Millipore, Stericup - GV, 0.22 ⁇ m Low Binding Duropore membrane) and the low molecular weight water-soluble components (DMSO, HSI and unbound TSPP) by ultrafiltration through a membrane with a 30 kD cut-off limit (Amicon YM 30 ) separated. A conjugate of TSPP and HSA was obtained. The coupling yield of TSPP to HSA was 85 to 90%.
• Pillar 1 Zorbax GF 450
• Pillar 2 Zorbax GF 450

Landscapes

• Health & Medical Sciences (AREA)
• Life Sciences & Earth Sciences (AREA)
• Engineering & Computer Science (AREA)
• Biomedical Technology (AREA)
• Chemical & Material Sciences (AREA)
• General Health & Medical Sciences (AREA)
• Immunology (AREA)
• Molecular Biology (AREA)
• Epidemiology (AREA)
• Medicinal Chemistry (AREA)
• Animal Behavior & Ethology (AREA)
• Public Health (AREA)
• Veterinary Medicine (AREA)
• Hematology (AREA)
• Urology & Nephrology (AREA)
• Biochemistry (AREA)
• Food Science & Technology (AREA)
• Organic Chemistry (AREA)
• Cell Biology (AREA)
• Physics & Mathematics (AREA)
• Analytical Chemistry (AREA)
• Biotechnology (AREA)
• General Physics & Mathematics (AREA)
• Pathology (AREA)
• Proteomics, Peptides & Aminoacids (AREA)
• Microbiology (AREA)
• Toxicology (AREA)
• Gastroenterology & Hepatology (AREA)
• Biophysics (AREA)
• Genetics & Genomics (AREA)
• Zoology (AREA)
• Investigating Or Analysing Biological Materials (AREA)
• Peptides Or Proteins (AREA)
• Nitrogen Condensed Heterocyclic Rings (AREA)
• Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
• Investigating Or Analysing Materials By The Use Of Chemical Reactions (AREA)

Applications Claiming Priority (3)

Publications (1)

Family

ID=7836699

Family Applications (1)

Country Status (5)

Families Citing this family (8)

Family Cites Families (14)

• 1997
  • 1997-07-23 DE DE19731741A patent/DE19731741A1/de not_active Withdrawn
• 1998
  • 1998-07-22 WO PCT/DE1998/002102 patent/WO1999005521A2/de not_active Application Discontinuation
  • 1998-07-22 EP EP98946241A patent/EP0998674A2/de not_active Withdrawn
  • 1998-07-22 US US09/463,474 patent/US20020037254A1/en not_active Abandoned
  • 1998-07-22 JP JP2000504456A patent/JP2001513583A/ja not_active Withdrawn
• 2004
  • 2004-08-13 US US10/917,907 patent/US20050019263A1/en not_active Abandoned

Non-Patent Citations (1)

Also Published As

Similar Documents

Legal Events